

**VIETNAM MEDICAL AND PHARMACEUTICAL  
INVESTMENT JOINT STOCK COMPANY**

**INTERIM SEPARATE FINANCIAL STATEMENTS**

**From 01/01/2026 to 31/03/2026**



**VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY**  
**INTERIM SEPARATE FINANCIAL STATEMENTS**

*Period from 01/01/2026 to 31/03/2026*

---

**CONTENTS**

	Page
Company Information	1-2
Statement of Financial Position	3-4
Income Statement	5
Cash Flow Statement	6 - 7
Notes to the Financial Statements	8 - 25

## **REPORT OF THE BOARD OF GENERAL DIRECTORS**

The Board of General Directors of VietNam Medical And Pharmaceutical investment Joint Stock Company (the “Company”) presents its report and the Company’s interim Separate financial statements period from 01/01/2026 to 31/03/2026.

### **THE COMPANY**

VietNam Medical And Pharmaceutical investment Joint Stock Company (“the Company”) formerly was established under the Certificate of Business Registration No. 0101178800 dated 27 September 2010 issued by the Hanoi Department of Planning and Investment and registered for the 24st change on 29 April 2026.

The Company's head office is located at 24 Floor, Icon4 Building, No. 243A De La Thanh Street, Lang Ward, Hanoi City.

### **BOARD OF MANAGEMENT, BOARD OF GENERAL DIRECTORSS AND BOARD OF SUPERVISION**

The members of the Board of Directors during the fiscal period and to the reporting date are:

Mr. Pham Thanh Nam	Chairman	(Since on 21/04/2026)
Mr. Vu Khanh Din	Chairman	(To 21/04/2026)
Mr. Pham Thanh Nam	Vice Chairman	(To 21/04/2026)
Mrs. Nguyen Thi Hanh	Member of BOD	(To 21/04/2026)
Mr. Nguyen Thi Phuong	Member of BOD	(To 21/04/2026)
Mr. Vu Van Toan	Vice Chairman	(Since on 21/04/2026)
Mr. Nguyen Van Chi	Member of BOD	
Mr. Le Tuan	Member of BOD	(Since on 03/11/2025)

The member of the Board of Management during the fiscal period and to the reporting date are:

- Mr. Vu Van Toan	CEO	(To 21/04/2026)
- Mr. Nguyen Ngoc Cuong	CEO	(Since 21/04/2026)

The members of the Board of Supervision are:

Mr. Do Duc Hiep	Head	(Since 21/04/2025)
Ms. Dang Thi Ha Giang	Member	
Ms. Nguyen Vu Y Tan	Member	(Since 21/04/2025)

### **STATEMENT OF THE BOARD OF MANAGEMENT’S RESPONSIBILITY IN RESPECT OF THE INTERIM SEPARATE FINANCIAL STATEMENTS**

The Board of Management is responsible for the interim Separate financial statements which give a true and fair view of the financial position of the Company, its operating results and its cash flows for the year. In preparing those interim Separate financial statements, the Board of Management is required to:

- Select suitable accounting policies and then apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the interim Separate financial statements;
- Prepare and present the interim Separate financial statements on the basis of compliance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to preparation and presentation of interim Separate financial statements;
- Prepare the interim Separate financial statements on going concern basis unless it is inappropriate to presume that the Company will continue in business.

**VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY  
COMPANY INFORMATION**

*Period from 01/01/2026 to 31/03/2026*

---

The Board of Management is responsible for ensuring that accounting records are kept to reflect the financial position of the Company, with reasonable accuracy at any time and to ensure that the interim Separate financial statements comply with the registered accounting system. It is responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

We, The Board of Management, confirm that the interim Separate financial statements give a true and fair view of the financial position as at 31 March 2026, its operation results and cash flows in the period from 01/01/2026 to 31/03/2026 of the Company in accordance with the Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to the preparation and presentation of interim Separate financial statements.

On behalf of the Board of Management



---

**Nguyen Ngoc Cuong**

General Director

*Ha Noi, 29 April 2026*

VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY  
Statement of Financial Position  
Period from 01/01/2026 to 31/03/2026

B01a-DN

ASSETS		Codes	Notes	Unit: VND	
				Ending balance	Opening balance
<b>A - CURRENT ASSETS</b>		<b>100</b>		<b>449,687,201,411</b>	<b>495,199,514,601</b>
<b>(100 = 110 + 120 + 130 + 140 + 150)</b>					
<b>I. Cash and cash equivalents</b>		<b>110</b>	<b>5</b>	<b>25,810,989,961</b>	<b>27,437,805,198</b>
1. Cash		111		24,390,989,961	26,017,805,198
2. Cash equivalents		112		1,420,000,000	1,420,000,000
<b>II. Short-term investments</b>		<b>120</b>		<b>14,156,109,949</b>	<b>13,656,109,949</b>
3. Investments held to maturity		123	6.1	14,156,109,949	13,656,109,949
<b>III. Short-term receivables</b>		<b>130</b>		<b>294,460,190,377</b>	<b>331,540,054,637</b>
1. Short-term trade receivables		131	7	225,571,827,348	210,387,278,972
2. Short-term advances to suppliers		132	8	58,235,654,262	133,595,024,105
3. Other short-term receivables		135		43,860,287,343	20,529,703,963
4. Allowance for doubtful short-term receivables		136	9	(33,207,578,576)	(32,971,952,403)
<b>IV. Inventories</b>		<b>140</b>	<b>11</b>	<b>113,556,547,829</b>	<b>120,498,416,949</b>
1. Inventories		141		137,529,362,110	140,949,717,219
2. Allowance for devaluation of inventories		149		(23,972,814,281)	(20,451,300,270)
<b>V. Other current assets</b>		<b>160</b>		<b>1,703,363,295</b>	<b>2,067,127,868</b>
1. Short-term prepaid expenses		161	12	1,374,587,848	2,029,726,600
2. Value added tax deductibles		162		37,401,268	37,401,268
3. Other receivables from State Budget		163		291,374,179	-
<b>B - NON-CURRENT ASSETS</b>		<b>200</b>		<b>505,207,580,709</b>	<b>514,077,524,575</b>
<b>(200 = 210 + 220 + 230 + 240 + 250 + 260)</b>					
<b>I. Long-term receivables</b>		<b>210</b>		<b>480,500,000</b>	<b>480,500,000</b>
6. Other long-term receivables		215	9	480,500,000	480,500,000
<b>II. Fixed assets</b>		<b>220</b>		<b>71,162,490,364</b>	<b>75,623,386,331</b>
1. Tangible fixed assets		221	13	71,162,490,364	75,611,034,803
<i>Historical cost</i>		222		432,151,310,808	435,501,435,277
<i>Accumulated depreciation</i>		223		(360,988,820,444)	(359,890,400,474)
3. Intangible fixed assets		227	14	-	12,351,528
<i>Historical cost</i>		228		3,610,757,500	3,610,757,500
<i>Accumulated depreciation</i>		229		(3,610,757,500)	(3,598,405,972)
<b>V. Long-term financial investments</b>		<b>260</b>		<b>427,297,179,151</b>	<b>430,550,000,000</b>
1. Investments in subsidiaries		261		310,603,000,000	310,603,000,000
1. Investments in associates		262	6.3	750,000,000	750,000,000
2. Other long-term investments		263	6.2	192,800,000,000	192,800,000,000
3. Allowance for long-term investments		264		(76,855,820,849)	(73,603,000,000)
<b>VI. Other long-term assets</b>		<b>270</b>		<b>6,267,411,194</b>	<b>7,423,638,244</b>
1. Long-term prepaid expenses		271	12	6,267,411,194	7,423,638,244
<b>TOTAL ASSETS (270 = 100 + 200)</b>		<b>280</b>		<b>954,894,782,120</b>	<b>1,009,277,039,176</b>

RESOURCES	Codes	Notes	Unit: VND	
			Ending balance	Opening balance
<b>C - LIABILITIES (300 = 310 + 330)</b>	<b>300</b>		<b>347,484,201,470</b>	<b>412,237,562,171</b>
<b>I. Current Liabilities</b>	<b>310</b>		<b>340,619,316,470</b>	<b>404,441,332,171</b>
1. Short-term trade payables	311	16	50,322,129,290	83,334,547,559
2. Short-term prepayments from customers	312	17	16,555,044,722	14,220,217,259
3. Short-term Taxes and other payables to State Budget	314	18	3,350,188,954	14,631,333,395
4. Payables to employees	315		1,940,534,769	6,242,336,961
5. Short-term accrued expenses	316	19	10,020,069,188	10,408,893,816
7. Other short-term payables	320	20	4,529,854,918	4,434,577,990
8. Short-term loans and finance leases	321	21	248,880,893,221	264,141,437,861
9. Provison for short-term payables	322		5,020,601,408	7,027,987,330
<b>II. Non-current liabilities</b>	<b>330</b>		<b>6,864,885,000</b>	<b>7,796,230,000</b>
4. Long-term loans and finance leases	339	21	6,864,885,000	7,796,230,000
<b>D - EQUITY (400 = 410)</b>	<b>400</b>		<b>607,410,580,650</b>	<b>597,039,477,005</b>
1. Owner's contributed capital	411	22	1,125,001,710,000	1,125,001,710,000
- Ordinary shares with voting rights	411a		1,125,001,710,000	1,125,001,710,000
2. Share premium	412		402,288,328,850	402,288,328,850
5. Investment and development funds	418		19,211,235,252	19,211,235,252
5. Retained earnings	420		(939,090,693,452)	(949,461,797,097)
- Retained earnings until last period	420a		(949,461,797,097)	(1,003,094,905,327)
- Retained earnings of this period	420b		10,371,103,645	53,633,108,230
<b>TOTAL RESOURCES (440 = 300 + 400)</b>	<b>440</b>		<b>954,894,782,120</b>	<b>1,009,277,039,176</b>

Preparer



Nguyen Thi Lua

Chief Accountant



Nguyen Thi Lua



Hanoi, 29 April 2026

Chief Executive Officer

ĐẦU TƯ

Y TẾ - DƯỢC PHẨM

VIỆT NAM

P. LĂNG - TP. HÀ NỘI

Nguyen Ngoc Cuong

**VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY**  
**INTERIM SEPARATE FINANCIAL STATEMENTS**  
 Period from 01/01/2026 to 31/03/2026

B02-DN/HN

ITEMS	Codes	Notes	Unit: VND			
			Quarter I 2026	Quarter I 2025	Accumulated from the beginning to the end of this quarter (This year)	Accumulated from the beginning to the end of this quarter (Last year)
1. Revenue from goods sold and services rendered	01	24	149,870,748,183	172,656,566,444	149,870,748,183	172,656,566,444
2. Revenue deduction	02	25	1,578,319,999	94,285,714	1,578,319,999	94,285,714
3. Net Revenue from goods sold and services rendered	10		148,292,428,184	172,562,280,730	148,292,428,184	172,562,280,730
4. Cost of goods sold	11	26	110,347,085,341	127,179,562,469	110,347,085,341	127,179,562,469
5. Gross profit from goods sold and services rendered (20=10-11)	20		37,945,342,843	45,382,718,261	37,945,342,843	45,382,718,261
6. Financial income	21	27	771,557,035	5,997,930,715	771,557,035	5,997,930,715
7. Financial expenses	22	28	7,533,994,603	2,848,149,863	7,533,994,603	2,848,149,863
7. Of which: interest expense	23		4,138,747,891	2,096,209,126	4,138,747,891	2,096,209,126
9. Selling expenses	25	29	11,363,116,765	15,421,241,689	11,363,116,765	15,421,241,689
10. General and Administration expenses	26	30	8,475,696,355	9,661,846,545	8,475,696,355	9,661,846,545
11. Operating profit (30=20+(21-22)+24-(25+26))	30		11,344,092,155	23,449,410,879	11,344,092,155	23,449,410,879
12. Other income	31	31	1,623,877,031	5,277,667,635	1,623,877,031	5,277,667,635
13. Other expenses	32	32	4,089,630	200,074,724	4,089,630	200,074,724
14. Profit from other activities (40=31-32)	40		1,619,787,401	5,077,592,911	1,619,787,401	5,077,592,911
15. Accounting profit before tax (50=30+40)	50		12,963,879,556	28,527,003,790	12,963,879,556	28,527,003,790
16. Current corporate income tax	51	33	2,592,775,911	5,705,400,758	2,592,775,911	5,705,400,758
18. Profit after tax (60=50-51-52)	60		10,371,103,645	22,821,603,032	10,371,103,645	22,821,603,032

Preparer



Nguyen Thi Lua

Chief Accountant



Nguyen Thi Lua



Nguyen Ngoc Cuong

**VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY**  
**INTERIM SEPARATE FINANCIAL STATEMENTS**  
**Period from 01/01/2026 to 31/03/2026**  
**(Indirect Method)**

**B03a-DN**

ITEMS	Codes	Notes	Cumulative This period	Cumulative Last period
<b>I. Cash flows from operating activities</b>				
<i>Profit before tax</i>	<i>01</i>		<i>12,963,879,556</i>	<i>28,527,003,790</i>
<i>Adjustment for</i>				
Depreciation and amortization and goodwill	02		1,110,771,498	4,985,332,213
Allowance and provisions	03		4,115,014,533	1,285,750,287
Foreign exchange gain (loss) upon revaluation of monetary items denominated in foreign currency	04		95,418,040	197,302,438
Gain/Loss from investing activities	05		2,395,426,978	(7,509,339,736)
Interest expenses	06		4,138,747,891	2,096,209,126
<i>Operating profit before working capital movements</i>	<i>08</i>		<i>24,819,258,496</i>	<i>29,582,258,118</i>
Increase, decrease in receivables	09		61,006,730,057	(66,526,429,675)
Increase, decrease in inventories	10		3,420,355,109	21,789,487,985
Increase, decrease in payables (exclude interest expense, CIT)	11		(36,791,870,576)	(52,346,005,015)
Increase, decrease prepayments	12		1,811,365,802	1,406,865,073
Interest paid	14		(4,113,202,185)	(2,068,410,505)
Coporate income tax paid	15		(12,380,536,180)	(8,500,000,000)
<i>Net cash from operating activites</i>	<i>20</i>		<i>37,772,100,523</i>	<i>(76,662,234,019)</i>
<b>II. Cash flows from investing activities</b>				
Acquisition of fixed assets and other long-term assets	21		-	(3,509,021,897)
Proceeds from disposals of fixed assets and	22		440,000,000	1,796,361,374
Cash outflow for lending, acquiring debt instruments of other entities	23		(30,053,777,278)	(356,500,000,000)
Cash recovered from lending, selling debt instruments of other entities	24		6,211,402,924	426,550,000,000
Cash outflow for investments in other entities	25		-	(46,926,000,000)
Interest earned, dividend an profit received	27		195,348,234	13,474,461,350
<i>Net cash from investing activities</i>	<i>30</i>		<i>(23,207,026,120)</i>	<i>34,885,800,827</i>

**JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY**  
**INTERIM SEPARATE FINANCIAL STATEMENTS**  
 Period from 01/01/2026 to 31/03/2026  
 (Indirect Method)

B03a-DN

ITEMS	Codes	Notes	Cumulative This period	Cumulative Last period
<b>III. Cash flows from financial activities</b>				
Proceeds from borrowings	33		129,971,406,137	135,660,895,485
Repayment for borrowings	34		(146,163,295,777)	(106,556,417,747)
<i>Net cash from financial activities</i>	<i>40</i>		<u><i>(16,191,889,640)</i></u>	<u><i>29,104,477,738</i></u>
<b>Net cash during the period</b>	<b>50</b>		<b>(1,626,815,237)</b>	<b>(12,671,955,454)</b>
<b>Cash and cash equivalents at the beginning</b>	<b>60</b>	<b>5</b>	<b>27,437,805,198</b>	<b>18,565,353,017</b>
<b>Cash and cash equivalents at the ending</b>	<b>70</b>	<b>5</b>	<u><b>25,810,989,961</b></u>	<u><b>5,893,397,563</b></u>

Preparer



Nguyen Thi Lua

Chief Accountant



Nguyen Thi Lua



Hà Nội, 29 April 2026

Chief Executive Officer

Nguyen Ngoc Cuong

**VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY****INTERIM SEPARATE FINANCIAL STATEMENTS****NOTES TO FINANCIAL STATEMENT**

For the 3-month period ending March 31, 2026

**1.1. Structure of ownership**

VietNam Medical And Pharmaceutical investment Joint Stock Company (“the Company”) formerly was Japan Medical Equipment Joint Stock Company, operated under the Certificate of Business Registration No. 0101178800 dated 27 September 2010 issued by the Hanoi Department of Planning and Investment and registered for the 24th change on 29 April 2026.

The Company’s head office is located at Floor 24, Icon4 Building, No. 243A De La Thanh Street, Lang Ward, Hanoi City.

The Company’s chartered capital is VND 1,125,001,710,000 equivalent to 112,500,171 shares, par value per share is VND 10,000.

Total employees of the group as at 31 March 2026 was 108 (at 01 January 2026 was 110)

**1.2. Operating industry and principal activities**

The Company’s principal activities include:

- Wholesale of medical equipment and instruments;
- Lease of medical equipment and instruments;
- Associate investment medical equipments;
- General clinic, specialits clinic and dental clinic;
- Pharmaceutical business.

**1.3. Normal production and business cycle**

The Company’s normal course of business cycle is no more than 12 months

**1.4. Corporate structure**

The Company have a branch located at No. 218 Tran Hung Dao Street, Cho Lon Ward, Ho Chi Minh City which operating in wholesales of medical machinery and equipments.

As at 31 March 2026, the Company have 03 subsidiaries and 01 associate company as follow:

Subsidiaries	Principal activites	Address	Ownership ratio	Voting right ratio
- Kyoto Medical Science Company Limited.,	No business operations in the first three months of 2026	Floor 24, Icon4 Building, No. 243A De La Thanh Street, Lang Ward, Hanoi City.	100%	100.00%
- Vietnam Japan Medical Technology Investment Joint Stock Company	General clinic, specialits clinic and dental clinic	Floor 1, No. 163 Hoang Cau Street, Dong Da Ward, Ha Noi City.	99%	99.00%
- VIETNAM PHARMACEUTICAL INVESTMENT AND TRADING JOINT STOCK COMPANY	Pharmaceutical business activities	Floor 24, Icon4 Building, No. 243A De La Thanh Street, Lang Ward, Hanoi City.	85%	85.20%
Subsidiaries	Principal activites	Address	Ownership ratio	Voting right ratio
- Viet Tin Medical Equipment Joint Stock Company	Traing medical equipments	No. 19 Vo Van Tan Street, 6 Ward, Ho Chi Minh City	25.00%	25.00%

**2 ACCOUNTING PERIOD AND ACCOUNTING CURRENCY**

2.1 The Company’s fiscal year begins on 01 Jan and ends on 31 Dec of the following year

2.2 The currency unit used in accounting period is Vietnam Dong (VND)

**3 ACCOUNTING STANDARDS AND ACCOUNTING SYSTEM APPLIED**

These financial statements are the separate financial statements of the parent company - Viet Nam MedicalL and Pharmaceutical Investment Joint Stock Company prepared for the year ended 31 March 2026.

The financial statements are expressed in Vietnamese Dong (VND) and prepared under the accounting principles in conformity with the Vietnamese corporate accounting system issued in pursuance of Circular No. 99/2025/TT-BTC dated 27 Octorber 2025, Vietnamese Accounting Standards, and the relevant statutory requirements applicable to financial reporting.

**4 Estimates**

The significant accounting policies, which have been adopted by the Company in the preparation of these financial statements, are as follows:

**4.1 Basis of preparation of financial statements**

The financial statements are prepared on the accrual basis (except for the information related to cash flows), under historical cost principle, based on the assumption of going concern.

**4.2 Estimates**

The preparation of financial statements in conformity with Vietnamese accounting standards, the Vietnamese corporate accounting system, and the relevant statutory requirements applicable to financial reporting requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. The actual number incurred may differ from the estimates and assumptions

**4.3 Cash and cash equivalent**

Cash reflects the full existing amount of the Company at the end of the accounting period, comprising cash on hand, demand deposits and cash in transit.

Cash equivalents include short-term investments with maturity less than 03 months since the date of investment, which can be converted easily into a certain amount of cash without any risk in conversion into cash at the reporting date and recorded following Vietnamese Accounting Standard No. 24 - Cash flow statement

**4.4 Conversion of foreign currencies**

During the period, transactions arising in foreign currencies are converted into VND at exchange rates ruling at the transaction dates or accounting book exchange rate. Foreign exchange differences arising from these transactions are recognized in financial income (if gain) and financial expense (if loss). Monetary items denominated in foreign currencies are translated using exchange rate ruling at the balance sheet date. Foreign exchange differences arising from revaluation are reflected in the foreign exchange rate differences account and the balance of this account is transferred to the financial income (if profit) or financial expense (if loss) at the end of the accounting period.

**4.5 Held to maturity investment**

Reflecting the investments that the Company has intention and ability to hold to maturity with remaining maturity not exceeding 12 months (short-term) and more than 12 months (long-term) from the reporting date (except trading securities), including time deposits (including treasury bills, promissory notes), bonds, commercial papers, preference stocks which the issuer is obliged to buy at a certain time in the future, held-to-maturity loans for the purpose of collecting periodic interest, other kinds of debt securities (e.g. investment in buying bad debts, etc.) and other held-to-maturity investments, not including those already presented in the items such as "cash equivalents", "receivables from short-term borrowings" and "receivables from long-term borrowings".

Held-to-maturity investments are initially recognized at cost, including purchase price and expenses related to the purchase of investments such as brokerage fees, transaction, advisory, tax fees and bank charges ... After initial recognition, these investments are recorded at recoverable value.

Interest incurred after the date of purchase of held-to-maturity investments, profit upon disposals or sale of held-to-maturity investments are recorded in financial income. Interest received before the investment date is deducted from the cost at the date of purchase.

The Company bases on the remaining term from the reporting date to classify held-to-maturity investments as long-term or short-term and perform revaluation of monetary items denominated in foreign currencies under the principle presented in note No. 4.4.

When having strong evidence indicating part or all of the investments may not be recoverable and the losses can be measured reliably, these losses are recorded in financial expenses in the year and reduced directly to the value of the investments. Provision for held-to-maturity investments is similar to receivables unlikely to recover, is made similarly to bad debts according to note No. 4.7.

**4.6 Other investment**

Investments in subsidiaries:

Reflecting the investments which the Company holds more than 50% voting rights and the right to control and govern the financial and operating policies of the investee (subsidiary) to gain economic benefits from the operation of such enterprise or the Company holds less than 50% voting rights but has below conditions:

- The other investors agreed to offer for the Company more than 50% of the voting rights;
- The Company has the right to govern the financial and operating policies under a statute or agreement;
- The Company has the right to appoint or remove the majority of the members of the Board of Directors or equivalent management level;
- The Company has the right to cast the majority of votes at the meetings of the Board of Directors or equivalent management level.

Investments in associates:

Reflecting the investments which the Company directly or indirectly holds from 20% to under 50% voting shares of the investee (associated company) without any other agreement.

Associated company is the company which the Company has significant influence but does not have right to control over the financial policies and activities. Significant influence represents the right to participate in making policy decisions about financial policies and business operations of the investee but not control those policies.

#### 4.7 Receivables and provision for doubtful debts

Receivables are monitored detailed under the original terms, remaining terms at the reporting date, the receivable objects, receivable foreign currencies and other factors for the Company's management purpose. The classification of receivables comprised of trade receivables, and other receivables shall comply with the principles:

- Trade receivables include commercial receivables incurred from purchase-sale transactions, including receivables from sale of exported goods under the trust for other entities;
- Other receivables include non-commercial or non-trading receivables, including: receivables from loan interests, deposit interests, amount paid on behalf of another party; receivables which the export trustor must collect from the trustee; receivables from penalties, compensation; advances; pledges, collaterals, deposits, assets lending...

The company bases on the remaining term at the reporting date receivables to classify as long-term or short-term and the revaluation of monetary items denominated in foreign currencies according to the principles as presented in the note No. 4.4.

Receivables are recognised not exceeding the recoverable value. Provision for doubtful debts is made for receivables that are overdue for six months or more, or when the debtor is in difficulty of solvency due to dissolution, bankruptcy, or similar difficulties in accordance with the prevailing corporate accounting system.

#### 4.8 Inventories

Inventories are stated at the lower of cost and net realisable value. Cost comprises purchase price, processing cost and other direct attributable expenses that have been incurred in bringing the inventories to their present location and condition. Net realisable value represents the estimated selling price less all estimated costs to completion and costs to be incurred in marketing, selling and distribution. Cost is calculated using the weighted average method. Inventories are recorded by perpetual method.

The provision for the devaluation of inventories is the excess of the inventories' cost over their net realizable value at the accounting year end and made in accordance with prevailing corporate accounting system.

#### 4.9 Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less accumulated depreciation. Tangible fixed assets are recognized under the historical cost.

The costs of tangible fixed assets arising from purchases and self-constructions comprise all costs of bringing the tangible fixed assets to their working condition for their intended use.

The cost of self-construction or manufactured assets are the actual construction or manufacturing cost plus installation and test running costs.

Costs incurred after initial recognition are recorded as increase in the historical cost of assets if they actually improve the current status in comparison with the initial standard status of the assets, such as:

- Parts of the tangible fixed asset are modified to extend their useful life or to increase their capacity; or
- Parts of the tangible fixed asset are upgraded to substantially increase product quality; or
- New technology process is applied to reduce operation expenses of the assets in comparison with before.

The costs incurred for repairs and maintenance aims to restore or maintain the ability to bring the economic benefits of the assets according to the initial standard status, do not meet one of the above conditions, are recognized in the operation costs during the year.

Tangible fixed assets are depreciated using the straight-line method over their estimated useful lives in accordance with Circular No. 45/2013/TT-BTC dated 25/04/2013 of the Ministry of Finance. The estimated useful lives are as follows:

Buildings and structures:	05 years
Machinery and equipment:	03 - 12 years
Motor vehicles:	06 - 10 years
Office equipment:	03 - 06 years

Loss or gain resulting from sales and disposals of tangible fixed assets is the difference between proceed from sales or disposals of assets and their residual values and is recognized in the income statement

#### 4.10 Intangible assets and amortisation

Intangible assets comprise software and are stated at cost less accumulated amortization. Software is measured initially at purchase cost and is amortized on a straight-line basis over an estimated useful life from 03 years to 06 years.

**4.11 Construction in progress**

The construction in progress is recorded at cost, including expenses directly related to (including borrowing costs by the Company's accounting policy) properties in the course of construction for production, equipment installed for the purpose of manufacturing, rental and management as well as related expenses to repairs of fixed assets. Depreciation of these assets, on the same basis as other assets, commences when the assets are ready for their intended use.

**4.12 Prepaid expenses**

Prepaid expenses are expenses which have already been paid but relate to results of operations of multiple accounting periods. The Company's prepaid expenses include the value of tools and supplies, cost of repairing Machinery and Equipments and others

**4.13 Payables**

The payables are monitored detailed under the original terms, the remaining terms at the reporting date, the payable objects, type of payables denominated in foreign currency and other factors according to the Company's management purpose. The classification of payables such as trade payables, other payables must be implemented the following principles:

-Trade payables include commercial payables incurred from purchase-sale transactions, including payables when imported goods under the trust;  
- Other payables include non-commercial or non-trading payables, including: payables for loan interest, dividend and earning payables; payables for financial investments; amount paid for the third party; amount which the trustor receives from relevant parties to pay under the entrusted import-export transactions; asset borrowings; payables for penalties, compensation; surplus assets without reason; payables for social insurance, medical insurance, unemployment insurance, trade union; collaterals, deposits received, etc.

The company bases on the remaining terms of payables at the reporting date to classify as long-term or short-term and perform revaluation of monetary items denominated in foreign currencies according to the principles as presented in the note No. 4.4.

The payables are recorded not less than the payment obligations. In the case of there is evidence that a loss likely occurs, the Company recognizes immediately a payable under the prudent principle.

**4.14 Payable provisions**

Provision for liabilities is recognized only if the following conditions are fulfilled: The Company is responsible for current liabilities (legal liability or joint liability) due to consequences of any happened event; Possible decrease in economic benefits requires the settlement of liabilities; and Provide a reliable estimation of liabilities' value.

Provision for liabilities is recorded at the best estimate of the amount paid for current liabilities as at the end of the accounting period.

**4.15 Loans and finance lease liabilities**

The loans and finance lease liabilities are monitored detailed for each loan object, loan agreement, and loan asset; for the term of loan and finance lease liabilities and type of foreign currency (if any). The loans and finance lease liabilities with the remaining term more than 12 months from the reporting date are presented as long-term loans and finance lease liabilities. The due loans and finance lease liabilities within the next 12 months from the reporting date are presented as short-term loans and finance lease liabilities

**4.16 Borrowing costs**

Borrowing costs include interests and other costs incurred directly related to the loans.

Borrowing cost is charged to operating expenses during the period when incurred, except for borrowing costs directly attributable to the construction or production of qualifying assets with appropriate time (more than 12 months) to put into use for the intended purposes or sales, which recorded in the value of capitalized assets whether it is subject to the fulfillment of certain conditions of Vietnamese Accounting Standard No. 16 - Borrowing cost. Borrowing costs directly attributable to the construction of fixed assets, investment properties can be capitalized even though the construction is less than 12 months.

**4.17 Revenue recognition**

Revenue from the sale of goods shall be recognized if it simultaneously meets the following conditions:

- (a)The Company has transferred the majority of risks and benefits associated with the right to own the products or goods to the buyer;
- (b)The Company no longer holds the right to manage the goods as the goods owner, or the right to control the goods;
- (c) revenue has been determined with relative certainty. When contracts define that buyers are entitled to return products, goods purchased under specific conditions, the Company shall only record turnovers if such specific conditions no longer exist and buyers are not entitled to return products, goods (unless the customer is entitled to return the goods under the form of exchange for other goods or services);
- (d)The Company has gained or will gain economic benefits from the good sale transaction; and
- (e)It is possible to determine the costs related to the goods sale transaction.

**VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY**  
**INTERIM SEPARATE FINANCIAL STATEMENTS**  
**NOTES TO FINANCIAL STATEMENT**

For the 3-month period ending March 31, 2026

Revenue recognition from services rendered if simultaneously satisfying the following conditions:

- (a) Revenue is measured reliably. When the contracts define that the customers are entitled to return service purchased under specific conditions, the Company shall only record revenue if such specific conditions do not exist and the customers are not entitled to return services provided;
- (b) The Company received or will receive economic benefits from the sale transactions;
- (c) The completed work is determined at the reporting date; and
- (d) Incurred costs for the transaction and the costs to complete the transaction of providing such services is determined.

Revenue from financial activities includes: comprises deposit interest, profit from bond investment, profit from financial investment cooperation contract, discounted payments, gains from foreign exchange differences and others (if any).

Other income reflects income arising from the events or separate transactions with normal business operations of the Company, besides the above revenue.

**4.18 Taxation**

Corporate income tax represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit before tax as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years (including loss carried forward, if any) and it further excludes items that are never taxable or deductible.

Deferred tax is recognized on differences between the carrying amounts of assets and liabilities and its tax base in the financial statements and is recognized using the balance sheet method. Deferred tax liability should be recognized for all taxable temporary differences, and deferred tax asset shall be recognized when it is probable that taxable profit will be available against so that temporary differences are deductible.

Deferred tax is calculated at the tax rates that are expected to apply in the year when the liability is settled or the asset realized. Deferred tax is recognized in the income statement, and recognized in the equity only when it relates to items charged or credited directly to equity.

Deferred tax assets and liabilities are offset when the company has a legally enforceable right to set off current tax assets against current tax liabilities, and when the deferred tax assets and the deferred tax liabilities relate to income taxes levied by the same tax authority and the Company intends to settle its current tax assets and liabilities on a net basis.

The determination of the taxes borne by the Corporation is based on the current interpretation of tax regulations. However, these regulations are subject to periodic variation and their ultimate determination depends on the results of the tax authorities' examinations.

Other taxes are paid in accordance with the prevailing tax laws in Vietnam.

**4.19 Related parties**

The parties are regarded as related parties of the Company if they have the ability to control or exercise significant influence over the Company in making financial and operating decisions or have the same key management personnel or jointly managed by another Company.

Individuals with the direct or indirect voting rights can impact significantly to the Company, including close family members of these individuals (parents, spouses, children, siblings).

Key management personnel have authority and responsibility for planning, managing and controlling the operation of the Company: the directors, the managers of the Company and close family members of these individuals.

The companies managed by these individuals mentioned above with direct or indirect voting rights or through these rights they can have a significant impact on the Company, including the companies owned by the leaders or major shareholders of the Company and the companies have the same key management personnel.

**5. Cash and cash equivalents**

	<u>31-Mar-26</u>	<u>01-Jan-26</u>
Cash in bank	24,390,989,961	26,017,805,198
<b>Total</b>	<b>24,390,989,961</b>	<b>26,017,805,198</b>
Cash equivalents	1,420,000,000	1,420,000,000
<b>Total Cash and cash equivalents</b>	<b>25,810,989,961</b>	<b>27,437,805,198</b>

**6 Financial investment**

**6.1 Short-term investments held to maturity**

	<u>31-Mar-26</u>	<u>01-Jan-26</u>
Term - Deposit	14,156,109,949	13,130,109,949
<b>Total</b>	<b>14,156,109,949</b>	<b>13,130,109,949</b>

**VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY**  
**INTERIM SEPARATE FINANCIAL STATEMENTS**  
**NOTES TO FINANCIAL STATEMENT**

For the 3-month period ending March 31, 2026

**6.2 Other short-term investments**

	31-Mar-26		01-Jan-26	
	Value	Provision	Value	Provision
<b>Investments in associates</b>	<b>310,603,000,000</b>	<b>(72,853,000,000)</b>	<b>310,603,000,000</b>	<b>(72,853,000,000)</b>
- KYOTO MEDICAL SCIENCE COMPANY LIMITED	72,853,000,000	(72,853,000,000)	72,853,000,000	(72,853,000,000)
- VIETNAM JAPAN MEDICAL TECHNOLOGY INVESTMENT JOINT STOCK COMPANY	24,750,000,000		24,750,000,000	
- VIETNAM PHARMACEUTICAL INVESTMENT AND TRADING JOINT	213,000,000,000		213,000,000,000	
<b>Investments in joint ventures</b>	<b>750,000,000</b>	<b>(750,000,000)</b>	<b>750,000,000</b>	<b>(750,000,000)</b>
- Viet Tin Medical Devices JSC	750,000,000	(750,000,000)	750,000,000	(750,000,000)
<b>Investments in other entities</b>	<b>192,800,000,000</b>		<b>192,800,000,000</b>	
TNG Investment and Construction Company Limited	140,000,000,000		140,000,000,000	
Other entities	52,800,000,000		52,800,000,000	
<b>Total</b>	<b>504,153,000,000</b>	<b>(73,603,000,000)</b>	<b>504,153,000,000</b>	<b>(73,603,000,000)</b>

**7 Short-term trade receivables**

	31-Mar-26	01-Jan-26
Bach Mai Hospital	25,706,810,859	-
Cho Ray Hospital	18,165,790,000	19,344,278,750
K Hospital	14,567,084,362	-
Kien An Hospital	-	25,474,050,000
Geriatric and Rehabilitation Hospital	-	11,259,500,000
Hop Luc General Hospital Company Limited	-	10,253,010,000
VIETNAM JAPAN MEDICAL TECHNOLOGY INVESTMENT JOINT STOCK COMPANY	14,050,976,386	13,543,301,800
Hoan My Technology Development Investment Company Limited	37,511,094,395	33,643,020,795
Other Customers	115,570,071,346	96,890,205,008
<b>Total</b>	<b>225,571,827,348</b>	<b>210,407,366,353</b>

**8 Short-term advances to suppliers**

	31-Mar-26	01-Jan-26
An Thanh Phat Medical Devices Ltd, Company	12,240,360,000	12,240,360,000
Microvention Inc	5,461,487,233	21,656,161,340
Hai Phat Medical Equipment Company Limited	35,695,000,000	93,818,635,996
Other Customers	4,838,807,029	5,879,866,769
<b>Total</b>	<b>58,235,654,262</b>	<b>133,595,024,105</b>

**9 Other receivables**

	31-Mar-26	01-Jan-26
<b>Short-term</b>		
Receivables from interests	309,340,508	185,268,524
Advances	12,303,461,283	12,308,204,257
Deposit	298,346,352	305,394,352
Receivable of BCC	23,025,000,000	3,025,000,000
Others	7,924,139,200	4,705,836,830
<b>Total</b>	<b>43,860,287,343</b>	<b>20,529,703,963</b>
<b>Long-term</b>		
Deposit	480,500,000	480,500,000
<b>Total</b>	<b>480,500,000</b>	<b>480,500,000</b>

VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY  
INTERIM SEPARATE FINANCIAL STATEMENTS  
NOTES TO FINANCIAL STATEMENT

For the 3-month period ending March 31, 2026

10 DOUBTFUL DEBTS

*Receivables that are overdue or not yet due but are doubtful of collection*

	31-Mar-26			01-Jan-26		
	<i>Historical cost</i>	<i>Allowance</i>	<i>Recoverable Amount</i>	<i>Historical cost</i>	<i>Allowance</i>	<i>Recoverable Amount</i>
<b>Short-term receivables</b>						
Huu nghi Viet Duc Hospital	3,231,100,000	(2,261,770,000)	969,330,000	3,231,100,000	(2,261,770,000)	969,330,000
Song Viet Ltd. Company	1,896,450,000	(1,896,450,000)	-	1,896,450,000	(1,896,450,000)	-
Other Customers	4,143,222,454	(2,564,911,833)	1,578,310,621	3,255,661,876	(2,329,285,660)	926,376,216
<b>Advance payments to suppliers</b>						
An Thanh Phat Medical Devices Ltd, Company	12,240,360,000	(12,240,360,000)	-	12,240,360,000	(12,240,360,000)	-
Toan Dan Law Firm Co., Ltd.	2,889,424,958	(2,889,424,958)	-	2,889,424,958	(2,889,424,958)	-
	31-Mar-26			01-Jan-26		
	<i>Historical cost</i>	<i>Allowance</i>	<i>Recoverable Amount</i>	<i>Historical cost</i>	<i>Allowance</i>	<i>Recoverable Amount</i>
<b>Total value of overdue other receivables</b>						
Other Customers	11,354,661,785	(11,354,661,785)	-	11,354,661,785	(11,354,661,785)	-
<b>Total</b>	<b>35,755,265,309</b>	<b>(33,207,578,576)</b>	<b>2,547,640,621</b>	<b>34,867,704,642</b>	<b>(32,971,952,403)</b>	<b>1,895,706,216</b>

11 Inventories

	31-Mar-26		01-Jan-26	
	<i>Historical cost</i>	<i>Allowance</i>	<i>Historical cost</i>	<i>Allowance</i>
Goods in transit	5,205,758,534	-	22,558,224,202	-
Goods for sales	111,610,406,656	(23,905,565,745)	107,036,247,034	(20,384,051,734)
Goods on consignment	20,713,196,920	(67,248,536)	11,355,245,983	(67,248,536)
<b>Total</b>	<b>137,529,362,110</b>	<b>(23,972,814,281)</b>	<b>140,949,717,219</b>	<b>(20,451,300,270)</b>

12 Short-term prepaid expenses, Long-term prepaid expenses

	31-Mar-26	01-Jan-26
<b>Short-term prepaid expenses</b>		
Dispatched tools and supplies	99,315,448	121,006,334
Others	1,275,272,400	1,908,720,266
<b>Total</b>	<b>1,374,587,848</b>	<b>2,029,726,600</b>
<b>Long-term prepaid expenses</b>		
Dispatched tools and supplies	134,257,053	164,659,759
Spare parts and replacement components	2,714,035,982	3,342,212,537
Others	3,419,118,159	3,916,765,948
<b>Total</b>	<b>6,267,411,194</b>	<b>7,423,638,244</b>

13 Tangible fixed assets

*Notes in accordance with Appendix No. 01*

14 Intangible fixed assets

*Notes in accordance with Appendix No. 02*

VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY  
INTERIM SEPARATE FINANCIAL STATEMENTS  
NOTES TO FINANCIAL STATEMENT

For the 3-month period ending March 31, 2026

15	Short-term trade payables	31-Mar-26		01-Jan-26	
		Outstanding balance	Repayment capability amount	Outstanding balance	Repayment capability amount
	FujiFilm Vietnam Co.,Ltd	14,108,239,311	14,108,239,311	40,241,235,896	40,241,235,896
	Danh Medical Instruments Ltd. Company				
	Konica Minolta Japan, Inc. - JPY	5,102,157,640	5,102,157,640	6,596,080,524	6,596,080,524
	United Imaging Healthcare Hong Kong Limited (UI) - USD			12,397,190,000	12,397,190,000
	Microvention Inc	26,410,003,056	26,410,003,056	18,802,669,306	18,802,669,306
	Others	4,701,729,283	4,701,729,283	5,297,371,833	5,297,371,833
	<b>Total</b>	<b>50,322,129,290</b>	<b>50,322,129,290</b>	<b>83,334,547,559</b>	<b>83,334,547,559</b>
16	Prepayments from customers		31-Mar-26		01-Jan-26
	Lang Son International Medical Company Limited		1,100,000,000		
	Kien An Hospital		1,692,450,000		
	Bach Mai Hospital		6,938,500,000		5,287,900,000
	K Hospital		3,593,400,000		3,593,400,000
	Hoan My Da Nang General Hospital Joint Stock Company				2,038,950,000
	Others		3,230,694,722		3,299,967,259
	<b>Total</b>		<b>16,555,044,722</b>		<b>14,220,217,259</b>
17	Taxes and other payables to State Budget <i>Notes in accordance with Appendix No. 03</i>				
18	Short-term Accrued Expenses		31-Mar-26		01-Jan-26
	Professional consulting expense		5,303,255,718		5,303,255,718
	Business Commission expense		4,273,510,343		4,687,880,677
	Interest expense		314,889,386		289,343,680
	Other accrued expenses		128,413,741		128,413,741
	<b>Total</b>		<b>10,020,069,188</b>		<b>10,408,893,816</b>
19	Other payables		31-Mar-26		01-Jan-26
	<i>Short-term other payables</i>				
	Trade union fee,SHUI		261,363,486		13,295,386
	Deposits and collaterals received		28,000,000		28,000,000
	Others		4,240,491,432		4,393,282,604
	<b>Total</b>		<b>4,529,854,918</b>		<b>4,434,577,990</b>
20	Loans and finance leases <i>Notes in accordance with Appendix No. 04</i>				
21	Changing in owner's equity <i>Notes in accordance with Appendix No. 05</i>				

VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY  
 INTERIM SEPARATE FINANCIAL STATEMENTS  
 NOTES TO FINANCIAL STATEMENT

For the 3-month period ending March 31, 2026

22	Equity	31-Mar-26		01-Jan-26	
		VND	%	VND	%
	Contributed capital	1,125,001,710,000	100%	1,125,001,710,000	100%
	<b>Total</b>	<b>1,125,001,710,000</b>	<b>100%</b>	<b>1,125,001,710,000</b>	<b>100%</b>
	Capital transactions with owners and dividend distribution, profit sharing:				
		31-Mar-26		01-Jan-26	
	Paid-in equity				
	+ Opening balance	1,125,001,710,000		1,125,001,710,000	
	+ Ending balance	1,125,001,710,000		1,125,001,710,000	
23	<b>Revenue from goods sold and services rendered</b>		<b>This period</b>		<b>Last period</b>
	Revenue from goods sold		138,961,577,146		157,837,831,068
	Revenue from services rendered		3,551,600,709		6,050,485,433
	Other revenue		7,357,570,328		8,768,249,943
	<b>Total</b>		<b>149,870,748,183</b>		<b>172,656,566,444</b>
	Revenue from related parties				
	- VIETNAM JAPAN MEDICAL TECHNOLOGY INVESTMENT JOINT STOCK COMPANY		782,870,629		1,986,711,757
	- Tasco Joint Stock Company		23,083,200		23,083,200
	<b>Total</b>		<b>805,953,829</b>		<b>2,009,794,957</b>
24	<b>Revenue deduction</b>		<b>This period</b>		<b>Last period</b>
	Revenue deduction		1,578,319,999		94,285,714
	<b>Total</b>		<b>1,578,319,999</b>		<b>94,285,714</b>
25	<b>Cost of goods sold and services rendered</b>		<b>This period</b>		<b>Last period</b>
	Cost of goods sold		105,070,594,532		121,414,438,294
	Cost of services rendered		2,235,252,684		1,999,733,442
	Cost of leasing investment properties		2,995,888,925		3,310,994,380
	Allowance for devaluation of inventories		45,349,200		454,396,353
	<b>Total</b>		<b>110,347,085,341</b>		<b>127,179,562,469</b>
26	<b>Financial Income</b>		<b>This period</b>		<b>Last period</b>
	Bank and loan interest		514,697,491		276,942,925
	Foreign exchange gains arising during the period		256,859,544		
	Profit from investment cooperation contracts				5,720,987,790
	<b>Total</b>		<b>771,557,035</b>		<b>5,997,930,715</b>
27	<b>Financial Expenses</b>		<b>This period</b>		<b>Last period</b>
	Interest expenses		4,138,747,891		2,096,209,126
	Foreign exchange losses arising during the period		43,819,692		554,638,299
	Foreign exchange losses from year-end revaluation		98,606,171		197,302,438
	Provision for impairment of investment in subsidiaries		3,252,820,849		
	<b>Total</b>		<b>7,533,994,603</b>		<b>2,848,149,863</b>

VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY

INTERIM SEPARATE FINANCIAL STATEMENTS

NOTES TO FINANCIAL STATEMENT

For the 3-month period ending March 31, 2026

29	Selling expenses	This period	Last period
	Raw materials	457,449,877	1,710,052,728
	Labour expenses	5,847,111,822	5,756,074,246
	Depreciation expenses	860,684,998	1,161,897,864
	Provision/Reversal of provision for product warranty	(1,690,337,489)	2,663,084,380
	Expenses of outsourcing services	3,406,592,726	3,507,040,801
	Other expenses in cash	2,481,614,831	623,091,670
	<b>Total</b>	<b>11,363,116,765</b>	<b>15,421,241,689</b>
30	Administrative expenses	This period	Last period
	Labour expenses	4,510,812,106	4,179,137,537
	Tools and stationery expenses	223,503,211	220,387,403
	Depreciation expenses	155,104,443	194,230,429
	Provision expenses	235,626,173	1,813,651,950
	Expenses of outsourcing services	1,928,863,613	1,545,967,421
	Other expenses in cash	1,421,786,809	1,708,471,805
	<b>Total</b>	<b>8,475,696,355</b>	<b>9,661,846,545</b>
31	Other income	This period	Last period
	Gain from liquidation, disposal of fixed assets	400,000,000	2,117,130,520
	Gains from revaluation of assets	1,223,877,031	3,158,542,267
	Others	-	1,994,848
	<b>Total</b>	<b>1,623,877,031</b>	<b>5,277,667,635</b>
32	OTHER EXPENSES	This period	Last period
	Others	4,089,630	200,074,724
	<b>Total</b>	<b>4,089,630</b>	<b>200,074,724</b>
33	Corporate income tax expense	This period	Last period
	Corporate income tax expense calculated on taxable income for the current	2,592,775,911	5,705,400,758
	<b>Total current corporate income tax expense</b>	<b>2,592,775,911</b>	<b>5,705,400,758</b>

Current corporate income tax payable is determined based on the taxable income for the current year. The Company's taxable income differs from the profit or loss reported in the Statement of Profit or Loss because taxable income excludes items of income and expenses that are subject to taxation or deductible in other periods, as well as items that are non-taxable or non-deductible for tax purposes. The current corporate income tax payable is calculated using the tax rates enacted as of the end of the interim reporting period.

34 OFF STATEMENT OF FINANCIAL POSITION ITEMS

Foreign currencies

	31-Mar-26	01-Jan-26
- USD	100	100
Doubtful debts written-off		
Object	Value	Solving Time
Trade receivables	59,267,731,518	31/03/2022
Other receivables	13,612,130,439	31/03/2022
Trade receivables	240,679,310,430	31/03/2025
Advances to suppliers	307,847,523,800	31/03/2025
Other receivables	584,571,745,440	31/03/2025
<b>Total</b>	<b>1,205,978,441,627</b>	Reason
		Unrecoverable
		Unrecoverable
		Unrecoverable
		Unrecoverable
		Unrecoverable



**VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY**  
**INTERIM SEPARATE FINANCIAL STATEMENTS**

B09a-DN

For the period ended 31 March 2026

**APPENDIX 01**

**13 Tangible Fixed Assets**

	Buildings and structures	Machinery	Office Equipments	Trasportation Vehicle	Others	Total
	VND	VND	VND	VND	VND	VND
<b>HISTORICAL COST</b>						
Balance on 01/01/2026	7,617,359,883	414,836,834,687	3,140,438,021	9,906,802,686	-	435,501,435,277
Liquidation, disposal	-	(3,350,124,469)	-	-	-	(3,350,124,469)
<b>Balance on 31/03/2026</b>	<b>7,617,359,883</b>	<b>411,486,710,218</b>	<b>3,140,438,021</b>	<b>9,906,802,686</b>	<b>-</b>	<b>432,151,310,808</b>
<b>ACCUMULATED DEPRECIATION</b>						
Balance on 01/01/2026	3,710,729,060	349,730,651,804	2,234,505,601	4,214,514,009	-	359,890,400,474
Depreciation	234,760,410	416,118,342	242,451,561	205,089,657	-	1,098,419,970
<b>Balance on 31/03/2026</b>	<b>3,945,489,470</b>	<b>350,146,770,146</b>	<b>2,476,957,162</b>	<b>4,419,603,666</b>	<b>-</b>	<b>360,988,820,444</b>
<b>CARRYING AMOUNT</b>						
Balance on 01/01/2026	3,906,630,823	65,106,182,883	905,932,420	5,692,288,677	-	75,611,034,803
<b>Balance on 31/03/2026</b>	<b>3,671,870,413</b>	<b>61,339,940,072</b>	<b>663,480,859</b>	<b>5,487,199,020</b>	<b>-</b>	<b>71,162,490,364</b>

**VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY**  
**INTERIM SEPARATE FINANCIAL STATEMENTS**

B09a-DN

For the period ended 31 March 2026

**APPENDIX 02**

**14 Intangible fixed assets**

	Unlimited-term land use rights		Limited-term land use rights		Software	Others	Total
	VND	VND	VND	VND			
<b>HISTORICAL COST</b>							
Balance on 01/01/2026	-	-	3,610,757,500	-	3,610,757,500	-	3,610,757,500
Balance on 31/03/2026	-	-	3,610,757,500	-	3,610,757,500	-	3,610,757,500
<b>ACCUMULATED DEPRECIATION</b>							
Balance on 01/01/2026	-	-	3,598,405,972	-	3,598,405,972	-	3,598,405,972
Depreciation	-	-	12,351,528	-	12,351,528	-	12,351,528
Balance on 31/03/2026	-	-	3,610,757,500	-	3,610,757,500	-	3,610,757,500
<b>CARRYING AMOUNT</b>							
Balance on 01/01/2026	-	-	12,351,528	-	12,351,528	-	12,351,528
Balance on 31/03/2026	-	-	-	-	-	-	-

**VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY**  
**INTERIM SEPARATE FINANCIAL STATEMENTS**

B09a-DN

For the period ended 31 March 2026

**APPENDIX 03**

**17 Short-term Taxes and other payables to State Budget**

	Opening balance		Arising during period			Ending Balance	
	Receivables 01/01/2026	Payables 01/01/2026	Payable amount	Decrease during the period	Increase due to consolidation	Receivables 31/03/2026	Payables 31/03/2026
	VND		VND			VND	
- Output VAT	-	2,633,648,855	7,140,744,434	8,500,030,516	-	-	756,548,355
- VAT of imported goods	-	-	2,375,479,749	2,375,479,749	-	-	-
- Importing and exporting tax	-	-	21,882,088	21,882,088	-	-	-
- Corporate income tax	-	19,132,166,841	2,592,775,911	12,380,536,180	-	-	2,592,775,911
- Personal income tax	-	231,375,293	2,274,113,004	1,862,834,283	-	291,374,179	-
- Environmental protection tax and other taxes	4,941,768	3,319,675,156	5,000,000	19,193,548	-	-	864,688
<b>Total</b>	<b>4,941,768</b>	<b>25,316,866,145</b>	<b>14,409,995,186</b>	<b>25,159,956,364</b>	<b>-</b>	<b>291,374,179</b>	<b>3,350,188,954</b>

**VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY**  
**INTERIM SEPARATE FINANCIAL STATEMENTS**

B09a-DN

For the period ended 31 March 2026

**APPENDIX 04**

**20 Loans and finance leases**

	01/01/2026	During period		31/03/2026
	VND	Increase	Decrease	VND
	Value/Repayment Capability	Value/Repayment Capability	Value/Repayment Capability	Value/Repayment Capability
<b>Short-term loans</b>				
BIDV - My Dinh Branch (1)	264,141,437,861	130,902,751,137	146,163,295,777	248,880,893,221
	17,200,802,390	4,642,037,410	14,550,120,952	7,292,718,848
MB - So giao dich 1 Branch (2)	34,521,863,960	-	34,521,863,960	-
Vietcombank - Ha Thanh Branch (3)	36,689,316,042	25,659,559,984	21,255,183,363	41,093,692,663
Vietinbank - Thang Long Branch (4)	77,374,059,705	51,933,080,530	29,954,321,334	99,352,818,901
TPBank - Hanoi Branch (5)	18,760,443,742	22,528,536,842	12,361,038,742	28,927,941,842
VPBank - Ngo Quyen Branch (6)	12,197,764,422	8,028,246,917	6,200,000,000	14,026,011,339
SHB Bank - Thang Long Branch (7)	67,397,187,600	18,111,289,454	27,320,767,426	58,187,709,628
<b>Total</b>	<b>264,141,437,861</b>	<b>130,902,751,137</b>	<b>146,163,295,777</b>	<b>248,880,893,221</b>

**20.2 Long-term loans and finance leases**

	01/01/2026	During period		31/03/2026
	VND	Increase	Decrease	VND
	Value/Repayment Capability	Value/Repayment Capability	Value/Repayment Capability	Value/Repayment Capability
<b>Long-term loans</b>				
Loans from banks and financial organizations	9,154,885,000	-	458,000,000	8,696,885,000

**VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY**  
**INTERIM SEPARATE FINANCIAL STATEMENTS**

**B09a-DN**

**For the period ended 31 March 2026**

	-	458,000,000
		8,696,885,000
<b>BIDV - My Dinh Branch (8)</b>		
<b>Total</b>		<b>8,696,885,000</b>

**Repayment schedule**

	<b>31/03/2026</b>	<b>01/01/2026</b>
	<b>VND</b>	<b>VND</b>
Within 12 months	1,832,000,000	1,832,000,000
Amounts payable after 12 months	<b>1,832,000,000</b>	<b>1,832,000,000</b>
	<b>6,864,885,000</b>	<b>7,322,885,000</b>

**Details related to loans:**

- (1) The loan under Credit Facility Agreement No. 01/2025/6453135/HĐTD dated July 17, 2025, between the Company and Joint Stock Commercial Bank for Investment and Development of Vietnam – My Dinh Branch. The total credit limit amounts to VND 24,000,000,000. The loan is used to supplement working capital for the Company's regular production and business activities. The applicable interest rate is specified in each loan drawdown agreement. The collateral for the loan includes term deposit contracts and the Company's fixed assets.
- (2) The loan under Credit Facility Agreement No. 311578.25.002.449769.TD dated June 26, 2025, between the Company and Military Commercial Joint Stock Bank – Transaction Center Branch 1. The total credit limit amounts to VND 140,000,000,000, with a loan term until June 26, 2026. The loan is used to supplement working capital for the Company's regular production and business activities. The applicable interest rate is specified in each loan drawdown agreement. The loan is secured by machinery and equipment, inventory, and the rights to collect receivables.
- (3) The loan under Credit Facility Agreement No. 24/8767425-CTD/018 dated May 20, 2025, between the Company and Joint Stock Commercial Bank for Foreign Trade of Vietnam – Ha Thanh Branch. The total credit limit amounts to VND 45,000,000,000. The loan is used to supplement working capital for the Company's regular production and business activities. The applicable interest rate is specified in each loan drawdown agreement. The loan is secured by term deposit contracts, fixed assets, and real estate of the Company and a third party.

**VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY**  
**INTERIM SEPARATE FINANCIAL STATEMENTS**

**B09a-DN**

**For the period ended 31 March 2026**

- (4) The loan under Credit Facility Agreement No. 06/2025-HĐCVHM/NHCT326-VIET NHAT dated June 06, 2025, between the Company and Vietnam Joint Stock Commercial Bank for Industry and Trade – Thang Long Branch. The total credit limit amounts to VND 120,000,000,000. The loan is used to supplement working capital for the Company's regular production and business activities. The applicable interest rate is specified in each loan drawdown agreement. The loan is secured by real estate and fixed assets of the Company and a third party.
- (5) The loan under Loan Agreement No. 667/2025/HĐTD/DDO signed on November 17, 2025, between the Company and Tien Phong Commercial Joint Stock Bank – Hanoi Branch. The total credit limit amounts to VND 120,000,000,000. The collateral includes term deposit contracts and the rights to receivables under credit facilities granted by TPB. The applicable interest rate is specified in each loan drawdown agreement.
- (6) The loan under Loan Agreement No. 200326/JVC dated March 20, 2026, between the Company and Vietnam Prosperity Joint Stock Commercial Bank – Ngo Quyen Branch. The total credit limit amounts to VND 70,000,000,000, with the applicable interest rate specified in each loan drawdown agreement. The collateral includes receivables arising from contracts under credit facilities granted by VPBank.
- (7) The loan under Credit Facility Agreement No. 0010/2025/HĐHM-PN/SHB.110601 dated July 10, 2025, between the Company and Saigon – Hanoi Commercial Joint Stock Bank (SHB) – Thang Long Branch. The total credit limit amounts to VND 280,000,000,000, with a term of 06 months from the date of disbursement. The applicable interest rate is specified in each loan drawdown agreement. The collateral includes equity interests in other entities and receivables arising from contracts under credit facilities granted by SHB..
- (8) The loan under Credit Facility Agreement No. 02/2025/6453135/HĐTD dated August 15, 2025, between the Company and Joint Stock Commercial Bank for Investment and Development of Vietnam – My Dinh Branch. The total credit limit amounts to VND 11,000,000,000, with a loan term of 60 months. The interest rate is subject to periodic adjustment. The loan is secured by the Company's fixed assets.

**VIETNAM MEDICAL AND PHARMACEUTICAL INVESTMENT JOINT STOCK COMPANY**  
**INTERIM SEPARATE FINANCIAL STATEMENTS**

B09a-DN

For the period ended 31 March 2026

**APPENDIX 05**

**21 Changing in owner's equity**

	Paid-in capital of owners	Share premium	Other capital of owners	Treasury stock	Retained Earnings	Non-controlling interest	Total
	VND	VND	VND	VND	VND	VND	VND
<i>Period from 01/01/2026 to 31/03/2026</i>							
Balance on 01/01/2026	1,125,001,710,000	402,288,328,850	19,211,235,252	-	(1,003,094,905,327)	-	543,406,368,775
Profit of the year	-	-	-	-	10,371,103,645	-	10,371,103,645
Balance on 31/03/2026	<b>1,125,001,710,000</b>	<b>402,288,328,850</b>	<b>19,211,235,252</b>	<b>-</b>	<b>(992,723,801,682)</b>	<b>-</b>	<b>553,777,472,420</b>

